JPRN-jRCT2080223155已完成1 期
Phase I Clinical Study of Crenezumab in Patients with Alzheimer's Disease
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
Crenezumab has an acceptable safety profile to Japanese patients with mild to moderate Alzheimer's Disease
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 <= 84age old（—）
- 性别
- All
入选标准
- •Diagnosed as having probable AD dementia based on the NIA-AA core diagnostic criteria, or diagnosed as having mild to moderate dementia due to AD based on DSM-V
- •-MMSE score is 18 to 28 at screening
排除标准
- •-Concurrent neurological disease other than AD that could affect cognitive function or history thereof.
- •-Meet the exclusion criteria of MRI at screening.
研究者
相似试验
已完成
1 期
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT02116569Janssen Pharmaceutical K.K.9
已完成
1 期
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055Solid TumorsAdvanced Solid MalignanciesCancerNCT00973076AstraZeneca19
已完成
1 期
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaLeukemia, Lymphocytic, Chronic, B-CellNCT00923182Genzyme, a Sanofi Company6
招募中
1 期
Clinical Study of SNK01 in Participants With Moderate Alzheimer's DiseaseModerate Alzheimer DiseaseNCT06189963NKGen Biotech, Inc.36
进行中（未招募）
2 期
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's DiseaseDementia ModerateDementia, MildAlzheimer DiseaseNCT06125951Actinogen Medical247